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Abstract
Background: High-throughput custom designed genotyping arrays are a valuable resource for biologically focused
research studies and increasingly for validation of variation predicted by next-generation sequencing (NGS)
technologies. We investigate the Illumina GoldenGate chemistry using custom designed VeraCode and sentrix array
matrix (SAM) assays for each of these applications, respectively. We highlight applications for interpretation of
Illumina generated genotype cluster plots to maximise data inclusion and reduce genotyping errors.
Findings: We illustrate the dramatic effect of outliers in genotype calling and data interpretation, as well as
suggest simple means to avoid genotyping errors. Furthermore we present this platform as a successful method
for two-cluster rare or non-autosomal variant calling. The success of high-throughput technologies to accurately
call rare variants will become an essential feature for future association studies. Finally, we highlight additional
advantages of the Illumina GoldenGate chemistry in generating unusually segregated cluster plots that identify
potential NGS generated sequencing error resulting from minimal coverage.
Conclusions: We demonstrate the importance of visually inspecting genotype cluster plots generated by the
Illumina software and issue warnings regarding commonly accepted quality control parameters. In addition to
suggesting applications to minimise data exclusion, we propose that the Illumina cluster plots may be helpful in
identifying potential in-put sequence errors, particularly important for studies to validate NGS generated variation.
Background
Commercially available genome-wide single nucleotide
polymorphism (SNP) arrays and high-throughput “cus-
tom designed” genotyping of targeted variants are desir-
able for biologically focused research. The generation of
next-generation sequencing (NGS) de novo and rese-
quencing data is contributing to the increased desire for
custom, high-throughput arrays for variant validation
and determination of allele frequencies [1,2]. For custom
designed genotyping, assay reliability and productivity is
considered more crucial than perhaps for genome-wide
association studies (GWAS). Variants are chosen to
answer a specific question, and therefore variant selec-
tion is more thoughtful and less redundant.
The Illumina platform (Illumina Inc., San Diego, CA,
USA) has proven reliable and efficient for a number of
high-throughput genotyping applications using DNA
extracted from several sources, [3-9]. VeraCode and
BeadArray technologies are used with the GoldenGate
assay (Illumina) developed for simultaneous determina-
tion of between 96 and 384 (VeraCode) and 96 and
1,536 (BeadArray) variants. GoldenGate chemistry
employs the use of allele specific oligo (ASO) hybridisa-
tion coupled with fluorescent labelled universal amplifi-
cation primers for genotype differentiation. In addition
to genotype information, automated data analysis pro-
vides measures of SNP and sample quality control (QC).
Previous studies have adopted guidelines suggested by
Illumina for determining assay and sample reliability
based on a quality score (GenCall score) calculated by
the degree of separation between homozygote and het-
erozygote clusters [7,10,11]. A value between 0 and 1 is
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erally used as the cut-off for the overall SNP and each
individual genotype, respectively. In addition to this
automated QC, investigators have applied statistical
methods such as Hardy-Weinberg equilibrium (HWE)
and tests for Mendelian consistency to filter reliable
assays [8,10,12-14].
In this study, we assess genotype information gener-
ated on custom-designed Illumina 96-SNP VeraCode
and BeadArray Sentrix Array Matrix (SAM) assays, for
optimal generation of accurate genotyping and NGS
generated variant validation. Application of strict analy-
sis parameters may lead to valuable genetic information
being lost. Alternatively, limited QC may result in the
addition of incorrect genotype calls confounding data
analysis. The SNP assays described in this study have
the potential of being disregarded or falsely included
during analysis based on the current QC selection cri-
teria. We discuss the importance of visually inspecting
each cluster plot, particularly for custom designed geno-
type arrays, and suggest strategies for interpreting data
in plots that would normally be discarded during the
QC process.
Methods
Sample and Genotyping Data Sets
Two sample data sets were used to assess and interpret
Illumina-generated genotype cluster plots. The first was
part of a gene/pathway targeted human prostate cancer
association study. In brief, DNA was extracted from
dried blood spots (Guthrie card) and genotyped using a
custom 96-plex VeraCode SNP array for 768 samples
(unpublished data). In the second study, DNA was
extracted from ear clippings of Tasmanian devils (Sarco-
philus harrisii). DNA was genotyped as part of a valida-
tion of sequence variation determined from minimal
coverage (0.3× versus 0.5×) of NGS de novo sequencing
data of two animals using the Roche/454 Titanium
chemistry (unpublished data). Genotype analysis was
performed using a custom 96-plex SAM array for 96
samples. For both studies, the GoldenGate genotyping
procedure was performed as outlined by Illumina [15].
Data analysis and genotype confirmation
Genotype calls were generated automatically using the
GenCall software version 3.1.3. Due to the potential of
intra-plate inconsistencies (e.g. variation in fluorescent
intensities), the eight VeraCode runs were assessed indi-
vidually. The genotype cluster plots generated by each
VeraCode and SAM assays were visually inspected for
quality of calls. Plots that appeared to be “unusually”
clustered (ie not following the typical “spread” predicted
in regards to software generated HWE or distance
between clusters (θ)) were further investigated by
selecting samples to assess by direct Sanger sequencing
for genotype confirmation. Samples were sequenced
using Big Dye Terminator v3.1 (AB, Foster City, CA,
USA) chemistry according to manufacturer’s guidelines
and sequenced on an AB 3730 genetic analyzer (AB).
Results
Effect of outliers on cluster formation (VeraCode)
Using the VeraCode technology we observed several
consistent examples of SNP cluster plots that appeared
to be incorrectly genotyped due to a combination of a
short θ and the presence of outlier DNA samples. In the
two examples discussed in this study (Figure 1), the pre-
sence of just three outlier samples in the original analy-
sis resulted in these outliers being incorrectly genotyped
as heterozygous and the true heterozygous samples
being grouped with the closely located homozygous
cluster (Figure 1A and 1C). Removal of these outliers
corrected the genotype calls (Figure 1B and 1D), yet
reduced the GenCall score from 0.52 to 0.45 for
rs8081356 (Figure 1A and 1B, respectively) and 0.67 to
0.41 for rs10096900 (Figure 1C and 1D, respectively). A
measure of HWE for these two SNPs, revealed that the
original analysis was not within the expected distribu-
tions (P = 1.707778E-20 and 7.727E-21 for rs8081356
and rs10096900, respectively) and thus may have been
excluded on this basis. Exclusion of the outlier samples
corrected for the deviation from HWE.
Two-cluster autosomal and non-autosomal SNP calling
(VeraCode)
For rare and single copy variants (male Y- and X-chro-
mosomes), genotyping technologies must accurately
perform two-cluster calling. In this study successful
two-cluster calling was observed for both rare autoso-
mal (i.e. homozygous wild-type and heterozygous;
rs17011642 Figure 2A) and single copy X-linked var-
iants (rs5919392 Figure 2C) as well as incorrect two-
cluster calling for both scenarios (rs12988908 Figure
2B and rs17217069 Figure 2D). The assay was termed
“incorrectly genotyped” when one or more cluster
plots across the eight VeraCode plates for that variant
was miss-called. Miss-calling was usually represented
by the heterozygous samples being assigned the homo-
zygous mutant genotype for rare variants (Figure 2B)
and vice versa for the X-linked variants (Figure 2D).
Although rs12988908 would have been rejected during
QC based on deviation from HWE (P = 1.529597E-23),
but not GenCall score (0.72), rs17217069 on the X
chromosome, would not have been detected as false
based on this selection criteria (HWE P = 0.82, Gen-
Call = 0.67). Incorrect two-cluster calling was observed
in just 4/17 (24%) of rare autosomal variants and 1/9
(11%) of X-linked variants.
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Page 2 of 6Figure 2 Two cluster calling. Rare variant and two-cluster genotyping was successful for the majority of samples assessed on the VeraCode
platform as demonstrated in rs17011642 (A). Incorrect rare variant calling was observed for SNP rs12988908, with the heterozygous samples
being called homozygous for the mutant allele (B). Non-autosomal variants were correctly genotyped in most cases as demonstrated in SNP
rs5919392 (C). Only one X-linked SNP, rs17217069 was incorrectly genotyped with the mutant allele being called heterozygous.
Figure 1 Effect of outliers on cluster formation. Exclusion of three outlier samples represented as heterozygous for rs8081356 (A) and
rs10096900 (C), corrected genotype clusters for both SNPs (B and D respectively). Correcting the genotype calls reduced the normalised θ
(distance between heterozygous and homozygous clusters).
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(VeraCode)
In the two examples highlighted in this section of the
study, rs10786712 and rs1632947, all samples were gen-
otyped by the automated GenCall software as homozy-
gous, despite having a validated minor allele frequency
>0.39 [16]. For both SNPs, the software generated three
marginally separated groups within the one genotype,
spread along the Y- and X-axis of the rs10786712 and
rs1632947 cluster plots respectively (Figures 3A and 3B).
Direct Sanger sequencing confirmed the presence of the
three different genotypes as indicated in Figure 3A and
3B. Sequencing did not reveal any other obvious varia-
tion in the sequence surrounding these SNPs that might
explain the unusual clustering.
Undefined cluster distribution in a de novo NGS
generated SNP array (SAM)
In a 96-plex SAM array generated to verify variants pre-
dicted from limited (0.3× versus 0.5× coverage) de novo
sequencing, only a single SNP was classified as a geno-
t y p ef a i l u r eb yt h es o f t w a r e .W ed e f i n e d1 9p l o t sa s
failures due to single allele calling. In the majority of
such cases (79%, 15/19), direct Sanger sequencing
revealed a single nucleotide error in the NGS generated
data surrounding the putative SNP. In the examples
highlighted in this study (TD102 Figure 4A and TD108
F i g u r e4 B ) ,as i n g l en u c l e o t ide immediately adjacent to
the putative SNP was mistakenly absent from the NGS
generated data, subsequently leading to incorrect ASO
design for the custom SAM array. The Illumina cluster
plots revealed partial segregation along the Y-axis of the
plot, which were confirmed as different genotype groups
(Figure 4A and 4B). It should be noted that the remain-
ing 4/19 genotyping failures remain undetermined, as
Sanger sequencing confirmed the NGS-generated
sequence.
Discussion
Large-scale custom-designed genotyping studies have
been made feasible by the development of high-through-
put technologies and improvements of automated geno-
type calling software. In this study we demonstrate how
simple applications for interpreting automatically
Figure 3 Undefined cluster distribution for verified human SNPs (VeraCode). The GenCall software failed to define genotypes for two
verified human SNPs, rs10786712 (A) and rs1632947 (B) genotyped on the VeraCode platform. Samples were poorly separated into three groups
along the Y- and X-axis of the cluster plot. These three groups represented the three different genotypes as indicated.
Figure 4 Undefined cluster distribution in a de novo NGS generated SNP array (SAM). Failure to define separate genotype clusters for
newly identified variants TD102 (A) and TD108 (B) was due to incorrect sequence input into the GoldeGate assay design software. The failure of
one ASO to bind resulted in the different genotype groups being separated by a difference in fluorescence intensity of one allele along the
Y-axis of the cluster plot.
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Page 4 of 6generated Illumina cluster plots can be used to avoid
spurious genetic associations as well as optimising data
inclusion and interpretation, particularly for custom
designed target arrays.
Variation in quality and quantity of DNA input, is
largely unavoidable in large-scale studies. In order to
limit the effect potential outlier DNA samples may
have on genotype calls, it is important to visually
inspect the genotype plots and exclude outliers as
demonstrated in this study (Figure 1). In addition to
illustrating the importance of visual analysis, these
examples (rs8081356 and rs10096900) emphasise the
need to adopt QC criteria that extends beyond the
GenCall score calculated by the Illumina analysis soft-
ware. For both variants, the GenCall score decreased
when the correct genotypes were applied (Figure 1B
and 1D), and is therefore not an optimal measure of
assay reliability in such scenarios.
Investigating the disease-causing potential of rare var-
iants (that are often missed on larger scale GWAS [17]),
can prove problematic for genotyping arrays. In this
s t u d yw ef o u n dt h eI l l u m i n aV e r a C o d ea n dS A Mt e c h -
nologies to be highly reliable for rare variant and single
allele (male sex chromosome) two-cluster calling. How-
ever, we also highlight in this study, potential QC pro-
blems that may arise for two-cluster genotyping. We
observed that HWE was successful as a measure of
assay reliability when interpreting autosomal rare variant
miss-calling, but was not suitable for single allele X-
linked variants. For this application, visual inspection of
cluster plots in combination with prior knowledge of
the variant statistics (e.g. location and population-speci-
fic allele frequency) would provide an adequate means
of determining assay success.
A growing number of laboratories are employing the
use of NGS technology to sequence as yet unclassified
genomes, as well as resequencing of human and human
disease-associated genomes. From the predicted
sequence variants generated by these projects, custom-
designed arrays are being employed for validation and
frequency determination. Although the optimal coverage
required to distinguish true sequence variation is highly
debatable, and dependent on the type of NGS platform
used, high-throughput genotyping platforms allow for
rapid, cost-effective validation at even minimal coverage.
The SAM array discussed in this study was developed
from long-read NGS information generated from mini-
mal coverage of two samples of an as yet unsequenced
species (unpublished data). In both the VeraCode assay,
custom designed to genotype 96 confirmed human var-
iants, and the SAM array, designed to verify newly iden-
tified variants from de novo generated NGS data, we
observed several examples of individual clusters being
partially segregated within the one genotype group
(Figure 3 and 4). Although this cannot be attributed to
miss-calling on the VeraCode assays (Figure 3), the unu-
sually grouped variants described on the SAM array
(Figure 4) were due to incorrect oligo design as a result
of miss-interpretation of de novo generated NGS data.
For variants TD102 and TD108, NGS results suggested
t h ep r e s e n c eo fa na d d i t i o n a l nucleotide immediately
adjacent to the variant site, which was the same as the
alternative allele of the putative variant. Direct Sanger
sequencing confirmed that this additional nucleotide
was not present and hence we observed varying binding
capabilities of only one ASO, resulting in the fluorescent
intensity of samples containing a mutant allele being
greater than those without. In addition to confirming
the presence of a variant at these locations, the unu-
sually clustered assays on the SAM array, prompted clo-
ser inspection (visual and Sanger sequencing) which
lead to the identification of NGS-generated sequencing
error. We therefore suggest that visual inspection and
closer investigation of unusually clustered scatter plots,
may provide information that exceeds the initial goal of
SNP validation and is a complimentary tool for NGS
data validation.
Conclusion
We demonstrate in this study, applications to optimise
and improve the efficiency of data analysis generated
using the Illumina GoldenGate chemistry using logical
interpretation of both rare and common genotyping
data. We also present this platform as a successful tool
for NGS variant validation, which is applicable to even
limited sequence coverage.
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